scholarly journals Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors

PPAR Research ◽  
2008 ◽  
Vol 2008 ◽  
pp. 1-9 ◽  
Author(s):  
Lars Tatenhorst ◽  
Eric Hahnen ◽  
Michael T. Heneka

The peroxisome proliferator-activated receptors (PPARs) are ligand-inducible transcription factors which belong to the superfamily of nuclear hormone receptors. In recent years it turned out that natural as well as synthetic PPAR agonists exhibit profound antineoplastic as well as redifferentiation effects in tumors of the central nervous system (CNS). The molecular understanding of the underlying mechanisms is still emerging, with partially controverse findings reported by a number of studies dealing with the influence of PPARs on treatment of tumor cells in vitro. Remarkably, studies examining the effects of these drugs in vivo are just beginning to emerge. However, the agonists of PPARs, in particular the thiazolidinediones, seem to be promising candidates for new approaches in human CNS tumor therapy.

Life ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 1168
Author(s):  
Deokho Lee ◽  
Yohei Tomita ◽  
William Allen ◽  
Kazuo Tsubota ◽  
Kazuno Negishi ◽  
...  

The burden of neurodegenerative diseases in the central nervous system (CNS) is increasing globally. There are various risk factors for the development and progression of CNS diseases, such as inflammatory responses and metabolic derangements. Thus, curing CNS diseases requires the modulation of damaging signaling pathways through a multitude of mechanisms. Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear hormone receptors (PPARα, PPARβ/δ, and PPARγ), and they work as master sensors and modulators of cellular metabolism. In this regard, PPARs have recently been suggested as promising therapeutic targets for suppressing the development of CNS diseases and their progressions. While the therapeutic role of PPARγ modulation in CNS diseases has been well reviewed, the role of PPARα modulation in these diseases has not been comprehensively summarized. The current review focuses on the therapeutic roles of PPARα modulation in CNS diseases, including those affecting the brain, spinal cord, and eye, with recent advances. Our review will enable more comprehensive therapeutic approaches to modulate PPARα for the prevention of and protection from various CNS diseases.


2021 ◽  
Vol 14 (10) ◽  
pp. 1025
Author(s):  
Claudia Sagheddu ◽  
Miriam Melis ◽  
Anna Lisa Muntoni ◽  
Marco Pistis

Common pathophysiological mechanisms have emerged for different neurological and neuropsychiatric conditions. In particular, mechanisms of oxidative stress, immuno-inflammation, and altered metabolic pathways converge and cause neuronal and non-neuronal maladaptative phenomena, which underlie multifaceted brain disorders. The peroxisome proliferator-activated receptors (PPARs) are nuclear receptors modulating, among others, anti-inflammatory and neuroprotective genes in diverse tissues. Both endogenous and synthetic PPAR agonists are approved treatments for metabolic and systemic disorders, such as diabetes, fatty liver disease, and dyslipidemia(s), showing high tolerability and safety profiles. Considering that some PPAR-acting drugs permeate through the blood–brain barrier, the possibility to extend their scope from the periphery to central nervous system has gained interest in recent years. Here, we review preclinical and clinical evidence that PPARs possibly exert a neuroprotective role, thereby providing a rationale for repurposing PPAR-targeting drugs to counteract several diseases affecting the central nervous system.


2016 ◽  
Author(s):  
◽  
Christopher M. Owens

Injuries to nerves vary in their consequences, from weakened sensation and motor function to partial or complete paralysis. In the latter case, affecting about twenty thousand Americans yearly, the injury is debilitating and results in a significant decrease in quality of life. Currently there is no effective treatment for damage to the central nervous system, in particular the spinal cord. Compared to the injuries to the central nervous system, damage in the peripheral nerves, is more common, with about sixty thousand occurrences annually. The cost of associated surgical procedures and due to loss of function is in the billions. In this thesis we present work towards the construction and testing of a fully cellular, patented nerve graft, one amongst the first of its kind. For the fabrication of the graft we are the first to employ bioprinting (either implemented through a special purpose 3D bioprinter or manually), a novel tissue engineering method rapidly gaining acceptance and utility. We first review the status of bioprinting. We then detail the fabrication process. Next we report on the testing of the graft in an in vivo animal model through electrophysiology and histology. This is followed by the introduction of a novel in vitro model, aimed at providing a fast, inexpensive and reliable method to test engineered nerve grafts. We describe our work on the optimization of the in vitro assay and then the testing of the graft using the optimized assay. We conclude with a summary of our accomplishments and make suggestions for some exciting future applications of our approach.


PPAR Research ◽  
2008 ◽  
Vol 2008 ◽  
pp. 1-6 ◽  
Author(s):  
Rosemary E. Teresi ◽  
Kristin A. Waite

Peroxisome proliferator-activated receptor gamma (PPAR) is a ligand-activated transcription factor, which belongs to the family of nuclear hormone receptors. Recent in vitro studies have shown that PPAR can regulate the transcription ofphosphatase and tensin homolog on chromosometen(PTEN), a known tumor suppressor.PTENis a susceptibility gene for a number of disorders, including breast and thyroid cancer. Activation of PPAR through agonists increases functional PTEN protein levels that subsequently induces apoptosis and inhibits cellular growth, which suggests that PPAR may be a tumor suppressor. Indeed, several in vivo studies have demonstrated that genetic alterations of PPAR can promote tumor progression. These results are supported by observations of the beneficial effects of PPAR agonists in the in vivo cancer setting. These studies signify the importance of PPAR andPTEN's interaction in cancer prevention.


1975 ◽  
Vol 228 (5) ◽  
pp. 1510-1518 ◽  
Author(s):  
R Spector ◽  
AV Lorenzo

Free myo-inositol (inositol) transport into the cerebrospinal fluid (CSF), brain, and choroid plexus and out of the cerebrospinal fluid was measured in rabbits. In vivo, inositol transport from blood into choroid plexus, CSF, and brain was saturable with an apparent affinity constant (K-t) of approximately 0.1 mM. The relative turnover of free inositol in choroid plexus (16 percent/h) was higher than in CSF 4percent/h) and brain (0.3percent/h) when meausred by tissue penetration of tracer [3-H]-labeled inositol injected into blood. However, the passage of tracer inositol was not greater than the passage of mannitol into brain when measured 15 s after a rapid injection of inositol and mannitol into the left common carotid artery. From the CSF, the clearance of inositol relative to inulin was saturable after the intraventricular injection of various concentrations of inositol and inulin. Moreover, a portion of the inositol cleared from the CSF entered brain by a saturable mechanism. In vitro, choroid plexuses, isolated from rabbits and incubated in artificial CSF, accumulated [3-H-labeled myo-inositol against a concentration gradient by a specific, active, saturable process with a K-t of 0.2 mM inositol. These results were interpreted as showing that the entry of inositol into the central nervous system from blood is regulated by a saturable transport system, and that the locus of this system may be, in part, in the choroid plexus.


2020 ◽  
Vol 17 (3) ◽  
pp. 1142-1152 ◽  
Author(s):  
Karl E. Carlström ◽  
Praveen K. Chinthakindi ◽  
Belén Espinosa ◽  
Faiez Al Nimer ◽  
Elias S. J. Arnér ◽  
...  

Abstract The Nrf2 transcription factor is a key regulator of redox reactions and considered the main target for the multiple sclerosis (MS) drug dimethyl fumarate (DMF). However, exploration of additional Nrf2-activating compounds is motivated, since DMF displays significant off-target effects and has a relatively poor penetrance to the central nervous system (CNS). We de novo synthesized eight vinyl sulfone and sulfoximine compounds (CH-1–CH-8) and evaluated their capacity to activate the transcription factors Nrf2, NFκB, and HIF1 in comparison with DMF using the pTRAF platform. The novel sulfoximine CH-3 was the most promising candidate and selected for further comparison in vivo and later an experimental model for traumatic brain injury (TBI). CH-3 and DMF displayed comparable capacity to activate Nrf2 and downstream transcripts in vitro, but with less off-target effects on HIF1 from CH-3. This was verified in cultured microglia and oligodendrocytes (OLs) and subsequently in vivo in rats. Following TBI, DMF lowered the number of leukocytes in blood and also decreased axonal degeneration. CH-3 preserved or increased the number of pre-myelinating OL. While both CH-3 and DMF activated Nrf2, CH-3 showed less off-target effects and displayed more selective OL associated effects. Further studies with Nrf2-acting compounds are promising candidates to explore potential myelin protective or regenerative effects in demyelinating disorders.


PPAR Research ◽  
2009 ◽  
Vol 2009 ◽  
pp. 1-9 ◽  
Author(s):  
Angela Tesse ◽  
Ramaroson Andriantsitohaina ◽  
Thierry Ragot

Activation of peroxisome proliferator-activated receptors (PPARs), and particularly of PPARαand PPARγ, using selective agonists, is currently used in the treatment of metabolic diseases such as hypertriglyceridemia and type 2 diabetes mellitus. PPARαand PPARγanti-inflammatory, antiproliferative and antiangiogenic properties in cardiovascular cells were extensively clarified in a variety of in vitro and in vivo models. In contrast, the role of PPARδin cardiovascular system is poorly understood. Prostacyclin, the predominant prostanoid released by vascular cells, is a putative endogenous agonist for PPARδ, but only recently PPARδselective synthetic agonists were found, improving studies about the physiological and pathophysiological roles of PPARδactivation. Recent reports suggest that the PPARδactivation may play a pivotal role to regulate inflammation, apoptosis, and cell proliferation, suggesting that this transcriptional factor could become an interesting pharmacological target to regulate cardiovascular cell apoptosis, proliferation, inflammation, and metabolism.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 2669-2669
Author(s):  
Richard A. Wells ◽  
Kenneth R. Chien ◽  
Pei-Hua Yen

Abstract The retinoid X receptor (RXR) acts as an obligate heterodimeric partner for multiple nuclear hormone receptors (NRs), including the retinoic acid receptor (RAR), thyroid receptor (TR), vitamin D receptor (VDR), and peroxisome proliferator-activated receptor (PPAR). Targeted disruption of RXRα in the mouse yields an embryonic lethal phenotype due to impairment of cardiac development. We have utilized a conditional knockout approach to investigate the roles of NR signaling in haematopoiesis. Bone marrow cells were isolated from a mouse homozygous for a targeted mutation in which exon IV of RXRα is flanked by loxP sites (RXRαfl/fl). This mutation permits normal expression of RXRα, but expression of cre recombinase results in excision of exon IV, abrogating expression of functional RXRα (RXRαko/ko). We employed a retrovirus to deliver cre to conditionally targeted haematopoietic cells. Lineage-depleted RXRαfl/fl bone marrow (BM) cells were transduced with a retrovirus that expresses a GFP-cre fusion, or with a control retrovirus expressing only EGFP. Transduced cells were isolated to >97% purity by FACS. The effect of RXRα disruption on haematopoiesis was assessed by in vitro assays and by transplantation into strain-matched lethally irradiated recipient mice. Progenitor assays performed in methylcellulose medium supplemented with haematopoietic growth factors revealed that GFP-cre - transduced (RXRαko/ko) grafts contain slightly fewer BFU-E and CFU-GM per 10,000 cells (60% and 80% of EGFP - transduced RXRαfl/fl cells, respectively). Long-term culture initiating cells (LTCIC) were enumerated for RXRαko/ko and RXRαfl/fl grafts. RXRα excision resulted in a moderate (25%) reduction in LTCIC. RXRαko/ko HSCs grown in suspension culture (IMDM supplemented with 10% foetal bovine serum, IL3, IL6, and kit ligand) for two weeks show reduced proportions of Mac1 positive (5% vs 27%) and Gr-1 positive (5% vs 12%) cells and strikingly increased CD117 positive cells (84% vs 49%). In vivo function of RXRαko/ko HSCs was evaluated by transplantation into lethally irradiated mice. Recipients were analyzed at 2, 4, and 6 weeks post-transplantation. Two weeks after transplantation, RXRαko/ko and RXRαfl/fl HSCs showed similar patterns of engraftment, with GFP-positive erythroid and myeloid cells found mainly in the spleen. At 4 weeks, recipients of RXRαfl/fl grafts showed significant BM engraftment of myeloid and erythroid lineages, while RXRαko/ko recipients exhibited minimal BM engraftment. At 6 weeks post-transplant, engraftment of RXRαfl/fl cells was well-established in both BM and spleen. RXRαko/ko HSCs showed minimal myeloid engraftment, but both spleen and BM were populated predominantly by Ter119 positive erythroid cells, which exhibit markedly dyserythropoietic morphology. This difference was reflected in peripheral blood counts; recipients of RXRαko/ko grafts were profoundly anaemic, thrombocytopenic, and neutropenic, and pronounced RBC polychromasia and poikilocytosis. These data indicate that disruption of RXRα in adult HSCs results in a modest reduction in early and committed progenitors in vitro, but profoundly disrupts ability to reconstitute haematopoiesis in a lethally irradiated recipient. Myeloid and megakaryocyte lineages do not engraft in recipients of RXRαko/ko HSCs. RXRαko/ko erythropoiesis is dysplastic and yields markedly abnormal erythrocytes. Further investigation is required to elucidate the multiple roles of RXRα in haematopoiesis.


Sign in / Sign up

Export Citation Format

Share Document